Boundless Bio (BOLD) 10% Owner Kevin Tang Buys $73K of Stock
Key Points
- Ten percent owner Kevin Tang purchased 31,069 shares of Boundless Bio, Inc. on October 19, 2026, at an average price of $2.33 per share.
- The transaction grew Tang's total holdings in the clinical-stage oncology company to 2,989,889 shares valued at roughly $72,518.
- Boundless Bio shares recently traded around $2.43, sitting above their 200-day moving average of $1.86.
Since the trade, $BOLD is up 5.2% to date (from the $2.31 close on Oct 19, 2026).
Get Boundless Bio text alerts
We text you when insiders, Congress, analysts or big funds move on $BOLD.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Boundless Bio, Inc. alert may contain errors. Disclosures
Ten percent owner Kevin Tang purchased 31,069 shares of Boundless Bio, Inc. (BOLD) on October 19, 2026. According to a Form 4 filing with the U.S. Securities and Exchange Commission, the shares were acquired at a price of $2.33 each, for a total value of $72,518.15.
BOLD
Boundless Bio, Inc.
Kevin Tang vs. the S&P 500
Hypothetical returns from Kevin Tang's disclosed trades, not real profit or advice. How we model this.
Inside Kevin Tang's Boundless Bio Trade
The purchase added 31,069 shares to Tang's holdings, representing a 1.05% increase in his personal stake. Following the transaction, which was filed on October 19, 2026, Tang directly owned 2,989,889 shares of the company. This follows his earlier purchase on June 25, 2026, when he acquired 146,390 shares.
Other Institutional Activity in Boundless Bio
Other large funds also adjusted their positions in the company earlier in the year. Arch Venture Management, LLC grew its holdings by 1,347,048 shares, ending with 2,694,095 shares worth about $6,546,651. Tang Capital Management, LLC grew its holdings by 1,279,938 shares, ending with 2,559,875 shares worth about $6,220,496. Adar1 Capital Management, LLC grew its holdings by 984,108 shares, ending with 1,968,216 shares worth about $4,782,765. Cormorant Asset Management, LP grew its holdings by 500,000 shares, ending with 1,000,000 shares worth about $2,430,000. Millennium Management Llc grew its holdings by 378,764 shares, ending with 478,639 shares worth about $1,163,092.
Boundless Bio, Inc. Stock Up 5.2%
Boundless Bio shares closed at $2.31 on the day of the trade. The stock recently traded around $2.43 as of October 20, 2026, which is up about 5.2% since the transaction. The stock has a market capitalization of roughly $56.15 million.
Recent Earnings
Boundless Bio reported a trailing-twelve-month loss per share of $2.85 and a return on equity of -67.9%.
Insider Buying and Selling at Boundless Bio, Inc.
Several company insiders acquired shares earlier in the year. On June 15, 2026, Jonathan Lim acquired 48,000 shares, Nancy Whiting acquired 32,000 shares, and Jennifer Lew acquired 32,000 shares. Later in June, Kevin Tang bought 146,390 shares at an average price of $2.48.
Analysts Set New Price Targets
Wall Street coverage remains limited, with a single analyst opinion establishing a mean price target of $4.00.
About Boundless Bio
Boundless Bio, Inc. is a clinical-stage oncology company based in San Diego, California. The firm focuses on developing therapies that target extrachromosomal DNA to help patients fighting oncogene-amplified cancers.
Bottom Line
Insider transactions provide a window into how major stakeholders view their companies. Investors tracking Boundless Bio will watch for upcoming financial reports and further SEC filings to monitor insider activity.
Related Filing Alerts
Source: Kevin Tang's Form 4 filing on $BOLD (Oct 19, 2026). Written by software, not financial advice. How we make alerts